CT ct
CT c
t CT
CT CT
ct
CT c
t CT
CT CT
ct
CT c
t CT
CT CT
ct
CT c
t CT
CT CT
ct
CT
ct C
T CT
CT ct
CT c
t CT
CT CT
ct
CT c
t
CT CT
CT ct
CT c
t CT
CT CT
ct
CT c
t CT
CT CT
ct
CT c
t CT
CT CT
ct
CT c
t CT
CT
CT ct
CT c
t CT
CT CT
ct
CT c
t CT
CT CT
ct C
T ct
CT CT
CT ct
CT c
t CT
CT CT
ct
CT c
t CT
CT CT
ct
CT c
t CT
CT CT
ct
CT
ct
CT CT
CT ct
CT c
t CT
CT CT
ct
CT
ct C
T CT
CT ct
CT c
t CT
CT CT
ct
CT c
t
CT
CT CT
ct
CT c
t CT
CT CT
ct
CT c
t
CT CT
CT ct
CT c
t CT
CT CT
ct
CT c
t
CT CT
CT ct
CT c
t CT
CT CT
ct
CT c
t
CT CT
CT ct
CT c
t CT
CT CT
ct
CT c
t
CT CT
CT ct
CT c
t CT
CT CT
ct
CT c
t
MR mr M
R MR M
R MR M
R mr
MR MR M
R MR M
R mr M
R MR
MR MR M
R mr M
R MR M
R MR
MR mr M
R MR M
R MR M
R mr
MR MR M
R MR M
R mr M
R MR
MR MR M
R mr M
R MR M
R MR
MR mr M
R MR M
R MR M
R mr
MR M
R MR M
R MR m
r MR M
R
MR M
R MR m
r MR M
R MR M
R
MR m
r MR M
R MR M
R MR
mr MR M
R MR M
R MR m
r MR
MR M
R MR M
R mr M
R MR
MR MR M
R mr M
R MR M
R
MR MR m
r MR M
R MR M
R
mr MR M
R MR M
R MR m
r
MR MR M
R MR M
R mr M
R
MR MR M
R MR m
r MR M
R
MR MR M
R mr M
R MR M
R
MR M
R mr M
R MR M
R MR
MR m
r MR M
R MR M
R
MR mr M
R MR M
R MR
PET pet PET PET pet PET PET pet
PET PET pet PET PET pet PET PET
pet PET PET pet PET PET pet PET
PET pet PET PET pet PET PET pet
PET PET pet PET PET pet PET PET
pet PET PET pet PET PET pet PET PET
pet PET PET pet PET PET pet PET PET
pet PET PET pet PET PET pet PET PET
pet PET PET pet PET PET pet PET PET
pet PET PET pet PET PET pet PET PET
pet PET PET pet PET PET pet PET PET
pet PET PET pet PET PET pet PET PET pet
PET PET pet PET PET pet PET PET pet
PET PET pet PET PET pet PET PET pet PET
PET pet PET PET pet PET PET pet PET PET
pet PET PET pet PET PET pet PET PET pet
PET PET pet PET PET pet PET PET pet PET
PET pet PET PET pet PET PET pet PET PET
pet PET PET pet PET PET pet PET PET pet
PET PET pet PET PET pet PET PET pet PET
PET pet PET PET pet PET PET pet PET PET pet
PET PET pet PET PET pet PET PET pet PET PET
pet PET PET pet PET PET pet PET PET pet PET
PET pet PET PET pet PET PET pet PET PET
pet PET
SPECT SPECT S
PECT SPECT SPECT sp
ect
SPECT S
PECT SPECT S
PECT SPECT spect
SPECT S
PECT SPECT S
PECT SPECT spect
SPECT SPECT S
PECT SPECT SPECT sp
ect SPECT
SPECT S
PECT SPECT SPECT sp
ect SPECT
SPECT SPECT S
PECT SPECT spect
SPECT SPECT
SPECT SPECT SPECT sp
ect SPECT S
PECT SPECT
SPECT SPECT sp
ect SPECT S
PECT SPECT S
PECT
SPECT spect
SPECT SPECT S
PECT SPECT SPECT sp
ect
SPECT S
PECT SPECT S
PECT SPECT spect
SPECT
SPECT S
PECT SPECT SPECT sp
ect SPECT S
PECT
SPECT SPECT SPECT sp
ect SPECT S
PECT SPECT
SPECT SPECT spect
SPECT SPECT S
PECT SPECT SPECT
spect
SPECT SPECT S
PECT SPECT SPECT sp
ect SPECT
SPECT SPECT S
PECT SPECT spect
SPECT SPECT S
PECT
SPECT SPECT sp
ect SPECT S
PECT SPECT S
PECT SPECT
spect
SPECT SPECT S
PECT SPECT SPECT sp
ect SPECT
SPECT SPECT S
PECT SPECT spect
SPECT SPECT S
PECT
SPECT SPECT sp
ect SPECT S
PECT SPECT S
PECT SPECT
spect SPECT S
PECT SPECT S
PECT SPECT spect
SPECT SPECT
SPECT S
PECT SPECT spect
SPECT SPECT S
PECT SPECT
SPECT spect
SPECT SPECT S
PECT SPECT SPECT sp
ect SPECT
SPECT S
PECT SPECT SPECT sp
ect SPECT S
PECT SPECT
SPECT SPECT spect
SPECT SPECT
Clinical protocols Clinical proto-
cols CLINICAL PROTOCOLS Clinical proto-
cols Clinical protocols Clinical protocols
Clinical protocols CLINICAL PROTO-
COLS Clinical protocols Clinical protocols Clinical
protocols Clinical protocols CLINICAL
PROTOCOLS Clinical protocols Clinical protocols
Clinical protocols Clinical protocols CLINI-
CAL PROTOCOLS Clinical protocols Clinical proto-
cols Clinical protocols Clinical protocols
CLINICAL PROTOCOLS Clinical protocols Clinical
protocols Clinical protocols Clinical protocols
CLINICAL PROTOCOLS Clinical protocols Clinical proto-
cols Clinical protocols Clinical protocols CLINI-
CAL PROTOCOLS Clinical protocols Clinical protocols
Clinical protocols Clinical protocols CLINICAL
PROTOCOLS Clinical protocols Clinical protocols Clinical
protocols Clinical protocols CLINICAL PROTOCOLS
Clinical protocols Clinical protocols
Qual
ity m
anag
emen
t Q
ualit
y m
anag
emen
t Q
ualit
y
man
agem
ent
Qualit
y m
anag
em
ent
Qua
lity m
anag
e-
men
t Q
ualit
y m
anag
emen
t Q
ualit
y m
anag
emen
t Q
ualit
y
man
agem
ent
Qualit
y m
anag
em
ent
Qua
lity m
anag
emen
t
Qu
ality
man
agem
ent
Qua
lity
man
agem
ent
Qua
lity
man
agem
ent
Qualit
y m
anag
em
ent
Qua
lity m
anag
emen
t
Qual
ity m
anag
emen
t Q
ualit
y m
anag
emen
t Q
ualit
y m
anag
e-
men
t Q
ualit
y m
anag
em
ent
Qua
lity m
anag
emen
t Q
ualit
y
man
agem
ent
Qua
lity
man
agem
ent
Qua
lity
man
agem
ent
Qualit
y m
anag
em
ent
Qua
lity m
anag
emen
t Q
ualit
y
man
agem
ent
Qua
lity
man
agem
ent
Qua
lity
man
agem
ent
Qualit
y m
anag
em
ent
Qua
lity m
anag
emen
t Q
ualit
y m
anag
e-
men
t Q
ualit
y m
anag
emen
t Q
ualit
y m
anag
emen
t Q
ualit
y
manag
em
ent
Qua
lity m
anag
emen
t Q
ualit
y m
anag
emen
t
Qua
lity
man
agem
ent
Qua
lity
man
agem
ent
Qualit
y m
anag
e-
ment
Qua
lity m
anag
emen
t Q
ualit
y m
anag
emen
t Q
ualit
y m
an-
agem
ent
Qua
lity
man
agem
ent
Qualit
y m
anag
em
ent
Qua
lity
man
agem
ent
Qua
lity
man
agem
ent
Qua
lity
man
agem
ent
Qua
lity
man
agem
ent
Qualit
y m
anag
em
ent
Qua
lity m
anag
emen
t Q
ualit
y
man
agem
ent
Qua
lity
man
agem
ent
Qua
lity
man
agem
ent
Qualit
y
manag
em
ent
Qua
lity m
anag
emen
t Q
ualit
y m
anag
emen
t Q
ualit
y
man
agem
ent
Qua
lity
man
agem
ent
Qualit
y m
anag
em
ent
Qua
lity
man
agem
ent
Qua
lity
Ap-propriate use crite
ria APPROPRIATE USE CRITERIA A
ppropria
te
use cri
teria A
ppropriate use criteria A
ppropriate use criteria
Appropriate use criteria A
PPROPRIATE USE CRITERIA Appro
priate
use cri
teria A
ppropriate use criteria A
ppropriate use criteria
Appropriate use criteria A
PPROPRIATE USE CRITERIA Appro
priate u
se
criteria A
ppropriate use criteria A
ppropriate use criteria Appropri-
ate use criteria A
PPROPRIATE USE CRITERIA Appro
priate u
se crite
ria
Appropriate use criteria A
ppropriate use criteria Appropriate use crite
ria
APPROPRIATE USE CRITERIA A
ppropria
te use
criteria A
ppropriate use
criteria A
ppropriate use criteria Appropriate use crite
ria APPROPRIATE USE
CRITERIA Appro
priate u
se crite
ria Appropriate use crite
ria Appropriate
use criteria Appropriate use crite
ria APPROPRIATE USE CRITERIA A
ppropria
te
use cri
teria A
ppropriate use criteria A
ppropriate use criteria Appropriate use
criteria A
PPROPRIATE USE CRITERIA Appro
priate u
se crite
ria Appropriate use
criteria A
ppropriate use criteria Appropriate use crite
ria APPROPRIATE USE
CRITERIA Appro
priate u
se crite
ria Appropriate use crite
ria Appropriate use
criteria Appropriate use crite
ria APPROPRIATE USE CRITERIA A
ppropria
te use
criteria
Appropriate use crite
ria Appropriate use crit
eria Appropriate use criteria A
ppropri-
ate use criteria A
ppropriate use criteria A
ppropriate use criteriaAppropriate use crite
ria
APPROPRIATE USE CRITERIA Appro
priate u
se crite
ria Appropriate use crite
ria Appropri-
ate use criteria Appropriate use crite
ria APPROPRIATE USE CRITERIA A
ppropria
te use
criteria A
ppropriate use criteria A
ppropriate use criteria Appropriate use crite
ria
APPROPRIATE USE CRITERIA Appro
priate u
se crite
ria
International Conference on
(IMIC 2016)
Integrated Medical Imaging in Cardiovascular Diseases
Vienna, Austria10‒14 October 2016
Organized by the International Atomic
Energy Agency
Atoms for Peace
Atoms for Peace
IAEA-CN-243
CONFERENCE SECRETARIAT
Scientifi c Secretariat of the Conference
Ms Diana Paez and Mr Ravi KashyapNuclear Medicine and Diagnostic Imaging SectionDivision of Human HealthDepartment of Nuclear Sciences and Applications
Mr Joao Alberto Osso JuniorRadioisotope Products and Radiation Technology SectionDivision of Physical and Chemical SciencesDepartment of Nuclear Sciences and Applications
Email address of the scientifi c secretariat
Administration and Organization
Ms Julie ZellingerConference Services SectionDivision of Conference and Document ServicesDepartment of ManagementTel.: +43 1 2600 21321Email: [email protected]
Conference web page
http://www-pub.iaea.org/iaeameetings/50808/International-Conference-on-Integrated-Medical-Imaging-in-Cardiovascular-Diseases-IMIC2016
Please include reference numberIAEA-CN-243 in all communications.
International Atomic Energy Agency
P.O. Box 100Vienna International Centre1400 Vienna, Austria
ct CT
CT CT C
TCT
CT CT c
t CT c
t CT
CT CTCT
CT ct C
T ct C
T CT C
T ctct
ct CT c
t CTCT
ct CT
CT CT c
t
CT CT C
T ct C
T ctct
CTCTCTCT ctct C
TCT
MRMR mrMR
MRMR MR
MRMR mr
MR MR
MRMR MR MR
MR MRmr
pet PET PET pet pet pet PET PET PET PETPETpet PETpet pet pet pet pet pet PETPET PET pet pet
PETPET PET PET PET PET pet pet pet PET PETPET pet pet PET PET PET pet PETPET
CTPETCTPETPET PET pet ct
pet ctpet PET PET pet CTCT
PETPETPET PET pet PET PET PET PET PET PET pet PET
PETPETPET PET pet
SPECTSPECT
SPECT SPECTSPECT
SPECT SPECTSPECT
SPECT SPECTSPECT
SPECT SPECTSPECT
SPECT SPECTSPECT
SPECT SPECTSPECT
SPECTSPECT
SPECT SPECT SPECT
SPECTSPECT SPECTSPECT
SPECT spect SPECTSPECTSPECTSPECTSPECTSPECT SPECT SPECT SPECT spect spect
SPECT SPECT SPECTSPECTSPECTSPECT SPECT SPECT spect spect SPECTSPECT
SPECTSPECT SPECT SPECT SPECT spect spect spect
SPECTSPECT SPECT SPECT spect spect spect
SPECTSPECT SPECT spect SPECTSPECT
spect spect SPECT SPECT
SPECTSPECT SPECT
SPECTSPECT SPECT spect spect
spect spect SPECT SPECTSPECTSPECT
SPECTSPECT SPECT
SPECTSPECT SPECT
Clinical protocols
CAL PROTOCOLS Clinical protocols Clinical proto
Clinical protocols Clinical protocols
CLINICAL PROTOCOLS Clinical protocols Clinical
protocols Clinical protocols
Clinical protocols
CLINICAL PROTOCOLS Clinical protocols Clinical proto-
cols
Clinical protocols CLINI
CAL PROTOCOLS
Qua
lity
man
agem
ent
Qua
lity
man
agem
ent
Qua
lity m
anag
e
Qual
ity m
anag
emen
t Q
ualit
y m
anag
emen
t
Qua
lity
man
agem
ent
Qua
lity m
anag
emen
t
Qual
ity m
anag
emen
t Q
ualit
y m
anag
emen
t Qu
ality
Q
ualit
y m
anag
emen
t Q
uality
man
agem
ent
Qual
ity m
anag
emen
t Q
ualit
y m
anag
emen
t Qu
ality
man
age
Qua
lity
man
agem
ent
Qua
lity m
anag
emen
t
man
agem
ent
Qua
lity
man
agem
ent
Quali
ty m
anag
emen
t
Qua
lity
man
agem
ent
Qual
ity
man
agem
ent
Qua
lity
man
agem
ent
Quali
ty m
anag
emen
t
Qua
lity
man
agem
ent
Qua
lity
man
agem
ent
APPROPRIATE USE CRITERIA
Appropriate use criteria Appropriate use criteria
Appropriate use criteria APPROPRIATE USE CRITERIA
use criteria Appropriate use criteria Appropriate use criteria
Appropriate use criteria APPROPRIATE USE CRITERIA Appropriate use
criteria Appropriate use criteria Appropriate use criteria
ate use criteria APPROPRIATE USE CRITERIA Appropriate use
criteria
Appropriate use criteria Appropriate use criteria Appropriate use criteria
APPROPRIATE USE CRITERIA Appropriate use
criteria
criteria Appropriate use criteria Appropriate use criteria
CRITERIA Appropriate use
criteria Appropriate use criteria
use criteria Appropriate use criteria APPROPRIATE USE CRITERIA
use criteria Appropriate use criteria Appropriate use criteria
criteria APPROPRIATE USE CRITERIA Appropriate use
criteria
criteria Appropriate use criteria Appropriate use criteria
CRITERIA Appropriate use
criteria Appropriate use criteria
Appropriate use criteria APPROPRIATE USE CRITERIA
Appropriate use criteria Appropriate use criteria Appropriate use criteria
Appropriate use criteria Appropriate use criteriaAppropriate use criteria
Appropriate use
criteria Appropriate use criteria
APPROPRIATE USE CRITERIA
Appropriate use criteria Appropriate use criteria
MRMR mr
MR MR MR
MR APPROPRIATE USE CRITERIA Appropriate use
criteria
Appropriate use criteria APPROPRIATE USE CRITERIA
Appropriate use criteria
BACKGROUND AND OBJECTIVES
The fi rst International Conference on Integrated Medical Imaging in Cardiovascular Diseases (IMIC 2013) held at the IAEA Headquarters in Vienna, Austria, gathered over 240 participants from more than 70 Member States and had the support of 12 professional organizations. Building on the success of this conference, IMIC 2016 will focus on the most recent advances in the use of integrated medical imaging in the management of CVDs and support the professional development in order to strengthen the capacities of Member States to tackle CVDs.
The conference will have the following objectives:
To evaluate the current status of medical imaging, including SPECT, PET, echocardiography, CT and MRI, in the management of CVDs;
To refl ect on challenges faced in developing countries;
To deliver supporting ‘know-how’ via continuing medical education programmes in the fi eld, including information on the relative merits and limitations of each imaging modality;
To improve the performance of clinical practice through ‘read with the experts’ sessions and workshops;
To interact with all professionals involved in the management of CVDs and provide them with state-of-the-art information on this fi eld;
To exchange information on current advances in the fi eld among leading clinical scientists from developed and developing countries; and
To identify future challenges and trends, as well as the role of the IAEA and other professional organizations in addressing these.
LIST OF TOPICS
Both academic and practice based papers in the following areas are welcome:
Member State experience with SPECT, PET, echocardiography, CT and MRI in the management of CVDs;
Use of hybrid imaging or integrated imaging in CVD management;
Setting up an integrated imaging facility;
Radiopharmaceutical production using cyclotrons and radionuclide generators including good manufacturing practices and quality assurance aspects with special reference to imaging agents for CVDs;
Issues of medical physics, instrumentation and image processing and analysis related to CVD imaging;
Quality management, quality control, quality assurance and audits in integrated medical imaging and nuclear medicine practice;
Radiation protection for personnel and dose reduction for patients; and
Ethic, leadership and education in integrated medical imaging.
TARGET AUDIENCE
Professionals involved in the practice of medical imaging in CVDs including: nuclear medicine physicians, radiologists, cardiologists,
radiochemists/radiopharmacists, medical physicists, technologists/radiographers and other practitioners and scientists working in all aspects of medical imaging.
KEY DEADLINES31 March 2016 Electronic submission of the
abstracts (including Forms A and B)
31 March 2016 Submission of grant applications (Forms A and C)
Mid May 2016 Notifi cation of acceptance of abstracts
Any participant not submitting a paper should still submit the Participation Form A through the appropriate authority as soon as possible (see conference webpage for further details).
ABSTRACT SUBMISSION
Abstracts must be submitted in electronic format through the IAEA’s browser-based fi le submission system available at the conference web page.
REGISTRATIONNo registration fee is charged.
LANGUAGEThe conference will be held in English.